Altimmune Inc to Host Key Opinion Leader Call on Pemvidutide Phase 1 Clinical Trial Results - Conference Call Transcript
Greetings, and welcome to the Altimmune, Inc. Key Opinion Leader call on pemvidutide under development for obesity and NASH. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. Will Brown, Chief Financial Officer. Thank you. You may begin.
Thank you, operator, and thank you, everyone, for participating in today's Key Opinion Leader call on the previously announced results of our 12-week Phase 1 clinical trial of pemvidutide in overweight and obese subjects. Leading the call today will be Dr. Scott Harris, Chief Medical Officer of Altimmune, along with Dr. Stephen Harrison, Key Opinion Leader. After the prepared remarks, we will open up the call for a Q&A session. As a reminder, this conference call is being recorded and will be available for audio rebroadcast on Altimmune's website at www.altimmune.com. Please click the webcast link on our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |